# The CARDIOPROTECT Trial

> **NCT07654426** · PHASE2 · RECRUITING · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 60 (estimated)

## Conditions studied

- Diffuse Large B-cell Lymphoma (DLBCL)
- Cardiotoxicity
- Lymphoma

## Interventions

- **DRUG:** Dexrazoxane
- **DRUG:** Dexrazoxane placebo
- **DRUG:** Doxorubicin
- **DRUG:** Liposomal Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine
- **DRUG:** Prednisone
- **DRUG:** Rituximab
- **DRUG:** Polatuzumab Vedotin

## Key facts

- **NCT ID:** NCT07654426
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-31
- **Primary completion:** 2030-12-31
- **Final completion:** 2035-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07654426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07654426, "The CARDIOPROTECT Trial". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07654426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*